Eligo Bioscience is a biotechnology company focused on the development of innovative microbiome therapies. The company leverages cutting-edge technology to engineer beneficial microbes that can specifically target and eliminate harmful bacteria, aiming to treat a range of diseases linked to the human microbiome.

David Bikard

Timothy K. Lu

Xavier Duportet

Luciano Marraffini

Eligo Bioscience

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

CRISPR Biotech Engineering is an early-stage genome editing company that is committed to using innovative CRISPR-Cas9 technology to improve human lives.

CRISPR Biotech Engineering

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

AGORANOV

Worldwide Innovation Challenge

European Commission

CARB-X

EASME - EU Executive Agency for SMEs

Seventure Partners

Khosla Ventures

Bpifrance

Sanofi Ventures

Exciting times at Eligo! Following our Series B announcement, we're gearing up to take the first-ever topical CRISPR therapy to the clinic. 
If you're eager to have a meaningful impact on the lives of millions of patients, we would love to hear from you. 
We are indeed on the lookout for passionate and driven individuals to join our Development, Finance, Synthetic Biology & Bioinformatics teams.

https://eligo.bio/careers/

🎉 News alert: We are thrilled to announce that we have just closed a $30 million financing round led by Sanofi Ventures, with the participation of Bpifrance (Innobio2), and our existing investors Khosla Ventures and Seventure Partners.

 🧬 This funding will enable us to advance and test in the clinic our CRISPR-based medicine for the 90M+ patients suffering from moderate-to-severe acne vulgaris. It will also help us to further develop our proprietary platform to address other immuno-inflammatory diseases, cancers, and infectious diseases.

 🚀 This is a defining moment for Eligo as this funding places us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome.

#CRISPR #SyntheticBiology #GeneEditing #Microbiome #Acnetreatment 

https://lnkd.in/ejTC-DXS

Metric
Company Name	Eligo Bioscience	Biotech 365	CRISPR Biotech Engineering	Neovacs S.A.
Symbol				ALNEV
MSH ID	BIO:ELIGO	COM:BIOTECH-365	COM:CRISPR-BTE	COM:NEOVACS
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Financial Services & Finance	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology Business Services	Biotechnology	Biotechnology
Country	FR	FR	GB	FR
Stage				Post-IPO Debt
Employee Count	42			22
Website	eligo.bio	biotech-365.com	crispr-bte.com	neovacs.com
LinkedIn	eligo-bioscience			neovacs
Founders

Metric
Market Cap		52.99K
Enterprise Value
Monthly Web Traffic	68
Web Traffic Growth	-0.57
Valuation
Raised Capital		4.77M

Metric
Revenue				563.41K
Revenue (LTM)
Revenue (NTM)
Gross Profit				-7.13M
EBITDA				-7.12M
Operating Income				-7.30M
Net Income				-9.24M
EPS				-0.00
Diluted EPS				-0.00
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				-9.71
Operating Profit Margin				-12.95
EBITDA Margin				-12.64
Net Profit Margin				-16.39
Return on Equity				-0.12
Return on Assets				-0.11
Return on Capital Employed				-0.14

BIO:ELIGO

Eligo Bioscience

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				5.78
EV Multiple				-0.04

Metric
Days Sales Outstanding
Days Payables Outstanding				1.22K
Days Inventory Outstanding
Operating Cycle				11.67K
Cash Conversion Cycle				11.39K
Asset Turnover				0.01

Metric
Operating Cash Flow				-2.02M
Free Cash Flow				-2.24M
Cash Flow to Debt				-1.47
Operating Cash Flow/Sales				-3.59
Free Cash Flow Yield				-0.00

Metric
Cash & Equivalents				936.97K
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization				0.06
Debt to Assets				0.02
Current Ratio				2.32
Quick Ratio				1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue